anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a nifedipine film-controlled slow-release pellet capsule. A slow-release film of the nifedipine film-controlled slow-release pellet utilizes Eurdragit RL 30D as a film-formation material. A pellet core of the nifedipine film-controlled slow-release pellet contains croscarmellose sodium having high water expansibility. Excipients comprise microcrystalline cellulose and lactose as fillers and PEG 4000 as a solubilizer. The pellet core comprises 5 to 20wt% of croscarmellose sodium. The slow-release film comprises Eurdragit RL 30D, triethyl citrate as a plasticizer, and talcum powder as an antiplastering aid, wherein preferably, a ratio of Eurdragit RL 30D to triethyl citrate to talcum powder is 30: 3: 4 and a film weight increasing ratio is in a range of 21 to 35%. After absorbing water, the nifedipine film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, the nifedipine film-controlled slow-release pellet keeps stable release performances in the period of validity.
The invention relates to a Chinese traditional medicine granule with the efficacies of expelling worms, protecting the liver and stopping bleeding and dysentery, including ten Chinese traditional medicines of southernwood, agrimony, dichroa febrifuga, garden burnet root, pulsatilla chinensis, golden buckwheat rhizome, thistle, white paeony root, radix astragali and liquorice. The invention is mainly used for treating the symptoms of intestinal tract bleeding, intestinal wall thickening and necrosis and intestinal mucosa shedding, etc. caused by chicken eimeria maxima, eimeria acervulina, eimeria necatrix and so on. The invention can alleviated the symptoms of dull standing, aphagia or anorexia, defecating bloody stool or whole blood, emaciation and poor growth of sick chickens caused by coccidiosis. The invention has the efficacies of expelling worms, protecting the liver and stopping bleeding and dysentery. By considering the short avian genital tract and the special physiological structure of inability to digest lignocellulose, the medicine is prepared into soluble granules which can quickly be dissolved into drinking water which is absorbed by sick chickens so as to achieve the purpose of quick effect.
Migraine is a common and disabling pain condition. Affective/cognitive processes, such as pain catastrophizing and emotional reactivity, often play a major role in migraine pain and disability. These processes may be just as important to target as the sensory aspect given their impact on outcomes and disability. Because of this cognitive/affective load that builds over time in migraine, we hypothesize A) migraineurs perceive affective pain processing differently than non-migraineurs and B) mind/body therapies that target these factors may be especially beneficial and may differentially impact the affective component of migraine pain. Evidence shows that meditation decreases affective (e.g., pain unpleasantness) over sensory (e.g., pain intensity) response to experimental pain and reduces pain by engaging brain regions important for cognitive and affective modulation of pain. By measuring both experimental and clinical pain, the study team will be able to test these hypotheses.
The invention discloses a new natural product amanita caesarea polysaccharide AC-1 and application thereof. The amanita caesarea polysaccharide AC-1 is composed of heteropolysaccharide according to the proportion of 2:1, wherein the heteropolysaccharide is composed of two kinds of monosaccharide. The antioxidation on DPPH- and ABTS+ free radicals, the inhibition ratio of the amanita caesarea polysaccharide AC-1 with the concentration being 1mg/ml for DPPH is 37.09%, and the inhibition ratio of the amanita caesarea polysaccharide AC-1 with the concentration being 6 mg/ml on DPPH can reach 89.74%. The IC50 value is 1.69 mg/ml. The inhibition ratio of the amanita caesarea polysaccharide AC-1 with the concentration being 1 mg/ml on ABTS is 88.51%, and the inhibition ratio of the amanita caesarea polysaccharide AC-1 with the concentration being 6mg/ml on ABTS can reach 97.63%. The IC50 value is 0.92 mg/ml.
We employed an experimental randomized block (RB) design; blocked on reservation where 157 were assigned to the intervention condition (Bii-Zin-Da-De-Dah (Listening to One Another) 14 week family based prevention program). The first 4 weeks of the program are oriented towards the Anishinabe cultural traditions and the traditional Anishinabe family. Weeks 5 through 8 focus on identifying feelings and how to manage negative feelings such as anger and sadness in positive ways. The last 6 weeks of the program focus on outside influences and how to build positive support systems. Prior to the intervention, we completed a pre-test with families in the experimental group. Following the program, we completed a post-test and a 6-month youth follow-up.
The invention relates to compositions of immunostimulating nucleic acids and to methods of using such compositions. T-containing nucleic acids include poly T sequence and/or have more than 25 percentT nucleotide residues. TG nucleic acids have TG dinucleotides. C-rich nucleic acids have at least one poly-C area and/or more than 50 percent S nucleotides. These nucleic acids function in a way similar to the nucleic acids containing CpG motifs. The invention includes also preferred CpG nucleic acids.
The study populations consist of a sample of the patient population (men aged 40-79 years) of a large, group model HMO and a community sample of men age 50-79. Follow-up interviews of men randomly assigned to the intervention and control groups are being conducted by telephone to assess issues related to prostate cancer screening and the men's use of the CD-Rom educational intervention. Preliminary results are available for the first 1304 follow-up interviews (interim response rate = 26%). Of 554 men randomized to receive the CD-ROM, 227 (41%) reported receiving the CD-ROM, and 78 (14%) used it in a computer. About 51% of these 78 men used the CD-ROM once only, while 42% used it twice, and 27% shared it with someone else. Most users reported learning some (44%) or a great deal (46%) of new information from the CD-ROM, and most reported that it helped them organize their thoughts about screening somewhat (44%) or a great deal (28%). About 19% indicated that the CD-ROM increased their uncertainty somewhat or a great deal about whether or not they want to be screened, 30% reported that the CD-ROM changed their feelings about whether or not they want to be screened somewhat, and 12% reported that it changed their feelings a great deal. Men who used the CD-ROM had higher education, higher income, higher levels of computer usage, and were more likely to have previously had a PSA test compared to non-users. No other subject characteristics were significantly related to use. Using randomized group assignment in an "intention to treat" analysis, prostate cancer knowledge was significantly higher in the intervention group; there were no differences between study groups in decisional conflict or realistic expectations. However, when comparing those who did and did not use the CD-ROM using multiple regression analysis and controlling for differences in age, race, education, income, insurance status, previous receipt of prostate cancer screening, and computer usage, use of the CD-ROM was significantly associated with higher prostate cancer related knowledge, lower decisional conflict, and more realistic expectations about risk of dying from prostate cancer. After controlling for differences between users and non-users we found evidence that the CD-ROM was effective in reducing decisional conflict, and increasing knowledge and realistic expectations related to prostate cancer screening.
Treatment consists in a cell suspension (5 million cells/mL) in aseptic buffered solution containing human expanded adipose-derived stem cells (eASCs) of allogeneic origin in disposable vials with no preservative agents. The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope.
Detergent compositions comprise a fluoronitrobenzonitrile and a diluent, together with a surface active agent.  The surface active agent may be ionic e.g. a soap or the sodium salt of an alkylated aromatic sulphonic acid or non-ionic e.g. an ether or ester of polyethylene glycol such as polyoxyethylene sorbitan monooleate. The compositions may be solid or liquid e.g. solutions, suspensions, or emulsions.  The invention also comprises soaps incorporating a fluoronitrobenzonitrile.ALSO:Mycobacteriostatic compositions comprise a fluoronitrobenzonitrile together with a diluent.  The compositions may be in the form of solutions, suspensions, emulsions, ointments, or dusting powders.  Surface active agents may be incorporated in the compositions.  One or more other compounds having fungistatic or bacteriostatic properties may also be included.  Materials, e.g. cloth, leather, wood, wood pulp, or agricultural products, that are subject to deterioration by bacterial or fungal action may be preserved by treatment with a fluoronitrobenzonitrile.  The fluorobenzonitriles may also be incorporated in soaps, paints, waxes and plastics.
This is a randomized, placebo-controlled, double masked, multicenter, Phase III study. Patients will be stratified by study center and randomized to Visudyne therapy or placebo in a 2:1 ratio, respectively. Patients will receive either a single intravenous dose of Visudyne or placebo followed 15 minutes after the start of the infusion by light application. Follow-up visits will occur every three months (+/- 2 weeks) for the duration of the study. Re-treatment may be administered every three months (through the Month 21 visit) if evidence of CNV leakage is detected by fluorescein angiography (as judged by the Investigator).

At baseline and at each follow-up visit, patients will undergo the following assessments: ophthalmic examination, best-corrected visual acuity, color fundus photography, and fluorescein angiography. Indocyanine green (ICG) angiography will be conducted at baseline, Month 12, and Month 24. Optical coherence tomography (OCT) will be done at baseline, Month 3, Month 6, Month 12, and Month 24. Adverse events and concomitant medications will be assessed throughout the study.
The invention discloses an acupuncture point combination method for treating cold and an acupuncture point paste used cooperatively, wherein the acupuncture point combination comprises six acupuncture points: the lung meridian from Zuize to Taiyuan is divided into four equal parts, three points, the fluid gate and the crane top; the treatment method comprises the following steps: disinfecting the skin of the acupoint area by a conventional method; six acupuncture points are needled; applying the acupoint plaster after the injection. The first advantage of the invention is lossless. Because the micro-needle shallow puncture mild compensation mode is adopted, no injury and side effect are generated to the human body, and the selected acupuncture points are far-end and very safe. The second effect is that the point prescription can be used in the early stage, the middle stage and the later stage of the cold, and is very effective. Thirdly, the medicine is convenient, has no too many contraindications in treatment, is convenient to operate, can be applied to acupuncture points by micro-needles, sticking needles or adhesive tapes, and can be effective in stimulating the acupuncture points. Fourthly, the needle is inserted into the skin and hair layer of the body without pain and superficial prick and obvious pain, and the function of dispersing the hair of the lung channel of hand taiyin can be effectively enhanced.
Depression is a major global health problem. Major depression was ranked as the third leading cause of the global burden of diseases in 2004 and is supposed to occupy the first place by 2030. Major depression is a complex and multifactorial symptom-complex while dysfunctions in various endocrine axes may be independent risk factors in the development of the affective illness. Some recent observations indicate a significant role of vitamin D regarding mood. Vitamin D3 receptors have been found in cerebral cortex, cerebellum, and the limbic system. The active form of vitamin D on the nervous system is associated with modifying the production and release of neurotrophic factors such as nerve growth factor (NGF) which is essential for neuron differentiation, as well as increasing the levels of glial cell line derived neurotrophic factor (GDNF). Vitamin D influence the expression of genes associated GABA-ergic neurotransmission. It also stimulates the expression of tyrosine hydroxylase which is responsible for catecholamines biosynthesis. Lately, positive influences of vitamin D upon patients suffering from MDD have been suggested. This area require further attention and confirmation as little work has been carried out in this field. So, the present study is an attempt to investigate the effect of vitamin D administration along with SSRIs in patients with MDD. The study would be a interventional one to be conducted in the department of Pharmacology and in the department of psychiatry, BSMMU. A total of 90 patients suffering from major depression will be selected according to inclusion and exclusion criteria. The diagnosis of patients suffering from major depression and the selection of SSRIs would be performed by medical officer of the Psychiatry department. After completing necessary formalities including informed consent of the patients, patient's data will be collected to measure baseline complaints of depression. The patients would be divided into two groups: group A and B. Group A would consist of 45 patients who will receive only SSRIs and Group B would consist of 45 patients who will receive SSRIs plus vitamin D (2000IU) orally once daily. Blood sample will be collected to measure serum vitamin D and calcium level at baseline. Then again blood sample will be collected to measure serum vitamin D level after 8 weeks of vitamin D administration. Regularity of medicine intake will be ensured over telephone, pill count, and from the patient's compliance sheet. The study has entails almost no potential risk to the patients. Patients would have every right to quit the experimental procedure any time during the experimentations if they desire each. However, it will be explained to them that the results of the present study may offer better prospects for similar patients in future, and that the present experimentations would carry no potential risk towards their health or their lives provided they strictly follow the instructions conducted to them.
BACKGROUND AND PURPOSE: Epigallocatechin gallate (EGCG), a natural antioxidant, has shown protective effect in many diseases. We explore the effect and potential regulatory mechanisms of EGCG in preeclampsia (PE)-like rats.
METHODS AND MATERIALS: PE was mimicked in pregnant rats. EGCG was orally administered at a dosage of 25(Low, L) or 50 mg/kg (High, H) from gestational day (GD) 6-17. The blood pressure signatures, heart rates were monitored. The 24-h proteinuria and serum were analyzed. On GD 18, rats were sacrificed, and pups and placentas were weighed. Kidneys and placentas were analyzed using immunohistochemistry (IHC) and hematoxylin-eosin staining (H&E). Placentas were examined using western blot for sFlt1, eNOS, Nrf2, HO-1, SLC7A11. MDA, GSH, GPx and Fe2+ were measured.
RESULTS: EGCG inhibits systolic blood pressure, BUN, CREA, ALT, AST, UA and proteinuria levels in PE-like rats. EGCG enhances the pup weight and crown-rump length and reduces the rate of fetus growth restriction in PE group. Endothelial dysfunction and infiltration of inflammatory cells were found in kidney cortex and placenta tissues in PE group and were inhibited by EGCG treatment. sFlt1 was activated in placentas in PE group and inhibited by EGCG while eNOS/Nrf2/HO-1 were inhibited in PE group and restored by EGCG. MDA and Fe concentrations were elevated in PE group and reduced by EGCG while the GSH level, SLC7A11 and the GPx activity were inhibited in PE group and restored by EGCG.
CONCLUSION: EGCG alleviates inflammation, endothelial dysfunction and placental ferroptosis, improves pregnancy outcomes in PE-like rats via eNOS/Nrf2/HO-1.
The Booster balloon therapy (i.e. partial occlusion of the CS lumen with a subsequent backward pressure elevation without obstructing the CS blood flow) will start immediately after a successful PCI of the culprit coronary lesion in the LAD, with TIMI-II flow restoration. The Booster balloon therapy will then be continued for up to 90 min, but not less than 60 min.
A growing number of patients are living with cancer or have a history of cancer leading to increasing adverse effects of treatment or disease necessitating emergency department (ED) consultation. Long-term cancer survivors are at higher risk of comorbidities causing a substantial increase in health care resource utilization. The most frequent reasons for cancer-related ED visits are dyspnea, fever, pain, gastrointestinal or neurological symptoms leading to high hospital and intensive care unit admission rates. Acute respiratory failure in cancer patients necessitates timely diagnostic testing, whereby computed tomography is superior to chest X‑ray. Delay in intensive care unit (ICU) admission or mechanical ventilation increases mortality. Febrile neutropenia is an emergency with urgent need for antibiotic treatment. Treatment of neutropenic and nonneutropenic patients with sepsis does not differ. Cardiovascular disease is now the second leading cause of long-term morbidity and mortality among cancer survivors. Immunotherapy can lead to substantial and in some patients life-threatening complications that may not easily be recognized in the ED. Cancer-specific emergencies such as leukostasis, tumorlysis or hypercalcemia rarely present to ED and require interdisciplinary care. The constantly growing cancer population is likely to increase ED utilization. Knowledge about cancer treatment and disease-associated complications is crucial for emergency physicians. Palliative care education should secure appropriate end-of-life care avoiding futile interventions.
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long term studies in animals to determine the carcinogenic potential of moxifloxacin have not been performed.

Moxifloxacin was not mutagenic in 4 bacterial strains (TA 98, TA 100, TA 1535, TA 1537) used in the Ames Salmonella reversion assay. As with other fluoroquinolones, the positive response observed with moxifloxacin in strain TA 102 using the same assay may be due to the inhibition of DNA gyrase. Moxifloxacin was not mutagenic in the CHO/HGPRT mammalian cell gene mutation assay. An equivocal result was obtained in the same assay when v79 cells were used. Moxifloxacin was clastogenic in the v79 chromosome aberration assay, but it did not induce unscheduled DNA synthesis in cultured rat hepatocytes. There was no evidence of genotoxicity in vivo in a micronucleus test or a dominant lethal test in mice.

Moxifloxacin had no effect on fertility in male and female rats at oral doses as high as 500 mg/kg/day, approximately 12 times the maximum recommended human dose based on body surface area) or at intravenous doses as high as 45 mg/kg/day, approximately equal to the maximum recommended human dose based on body surface area). At 500 mg/kg orally there were slight effects on sperm morphology (head-tail separation) in male rats and on the estrous cycle in female rats.

13.2 Animal Toxicology and/or Pharmacology

Fluoroquinolones have been shown to cause arthropathy in immature animals. In studies in juvenile dogs oral doses of moxifloxacin 30 mg/kg/day or more (approximately 1.5 times the maximum recommended human dose based upon systemic exposure) for 28 days resulted in arthropathy. There was no evidence of arthropathy in mature monkeys and rats at oral doses up to 135 and 500 mg/kg/day, respectively.

Moxifloxacin at an oral dose of 300 mg/kg did not show an increase in acute toxicity or potential for CNS toxicity (for example, seizures) in mice when used in combination with NSAIDs such as diclofenac, ibuprofen, or fenbufen. Some fluoroquinolones have been reported to have proconvulsant activity that is exacerbated with concomitant use of NSAIDs.

A QT-prolonging effect of moxifloxacin was found in dog studies, at plasma concentrations about five times the human therapeutic level. The combined infusion of sotalol, a Class III antiarrhythmic agent, with moxifloxacin induced a higher degree of QTc prolongation in dogs than that induced by the same dose (30 mg/kg) of moxifloxacin alone. Electrophysiological in vitro studies suggested an inhibition of the rapid activating component of the delayed rectifier potassium current (IKr) as an underlying mechanism.

No signs of local intolerability were observed in dogs when moxifloxacin was administered intravenously. After intra-arterial injection, inflammatory changes involving the peri-arterial soft tissue were observed suggesting that intra-arterial administration of Moxifloxacin Hydrochloride should be avoided.
The present invention relates to a method for preparing a low temperature-extracted IpmoeabatatasL. Lam composition with antioxidant activity and antithrombotic activity, and a use thereof. According to the method of the present invention, the IpmoeabatatasL. Lam composition is prepared by extracting a IpmoeabatatasL. Lam with hot water at 50 to 70°C, cooling and concentrating the same to prepare an IpmoeabatatasL. Lam concentrate, and adding purified water to the IpmoeabatatasL. Lam concentrate to adjust the same to 25 to 35 brix.
Ethinyl estradiol and norethindrone are rapidly absorbed with maximum plasma concentrations occurring within 2 hours after norethindrone and ethinyl estradiol administration (see Table 1). Norethindrone appears to be completely absorbed following oral administration; however, it is subject to first-pass metabolism resulting in an absolute bioavailability of approximately 65%. Large intersubject variability is reflected in a 3- to 5-fold variation in norethindrone bioavailability. Ethinyl estradiol bioavailability is approximately 43% due to small-intestinal and hepatic first-pass metabolism.

Effect of Food. Single-dose administration of norethindrone and ethinyl estradiol tablets, chewable with food decreased the maximum norethindrone and ethinyl estradiol concentration by 53% and 47%, respectively; the extent of norethindrone and ethinyl estradiol absorption (AUC values) was not affected by food administration.